Oportunidade De Mercado De Diagnóstico Do Câncer De Rim Na Europa Até 2030

Europe Kidney Cancer Diagnostics Market

Tamanho do mercado em biliões de dólares

CAGR : 6.10 %

Período de previsão	2023 –2030
Tamanho do mercado (ano base )	US$ MILHÕES Pedido
Tamanho do mercado ( Ano de previsão)	USD 3,572.63
CAGR	6.10 %
Principais participantes do mercado	Manequim1 Manequim2 Manequim3 Manequim4 Manequim5 Pedido de desbloqueio

>Mercado europeu de diagnóstico de cancro do rim, por tipo de teste (imagiologia, teste de biomarcador, teste sanguíneo, biópsia, teste genético e outros), estádio de cancro (estádio I, estádio II, estádio III e estádio IV), tipo de tumor (carcinoma de células renais) , Carcinoma de células renais de células claras, Carcinoma de células renais de células não claras), Produto (produtos baseados em plataforma, produtos baseados em instrumentos, kits e reagentes e outros consumíveis), tecnologia ( hibridização in situ fluorescente , sequenciação de nova geração, imunoensaio fluorescente, hibridização genómica comparativa , Imunohistoquímico e Outros), Aplicação (Rastreio, Diagnóstico e Preditivo, Prognóstico e Investigação), Utilizador Final (Hospitais, Centros de Diagnóstico, Centros de Investigação do Cancro, Institutos Académicos , Centros Cirúrgicos de Ambulatório e Outros), Canal de Distribuição (Concurso Directo, Vendas a Retalho e Outros), Tendências do Sector e Previsão para 2030.

Análise e dimensão do mercado de diagnóstico de cancro renal na Europa

O cancro renal começa quando as células saudáveis num ou em ambos os rins se alteram e crescem incontrolavelmente, formando uma massa chamada tumor cortical. O tumor pode ser maligno, indolente ou benigno. A malignidade é cancro, o que significa que pode crescer e espalhar-se para outras partes do corpo. Um tumor indolente é também cancro, mas este tipo de tumor raramente se espalha para outras partes do corpo. Um tumor benigno significa que o tumor pode crescer, mas não se espalhar.

A crescente consciencialização sobre o cancro do rim na Europa aumentou a procura do mercado. O aumento dos gastos em saúde para melhores serviços de saúde também contribui para o crescimento do mercado. Os principais players do mercado concentram-se em diversos lançamentos e aprovações de serviços durante este período crucial. Além disso, o aumento da melhoria dos procedimentos de diagnóstico do cancro do rim também contribui para o aumento da procura de testes de diagnóstico do cancro do rim.

Espera-se que o mercado europeu de diagnóstico do cancro do rim cresça no ano previsto devido ao aumento dos participantes no mercado e à disponibilidade de serviços avançados. A par disto, os fabricantes estão empenhados em atividades de I&D para lançar novos serviços no mercado. Espera-se que a crescente investigação na área do diagnóstico e desenvolvimento renal impulsione ainda mais o crescimento do mercado. No entanto, prevê-se que os danos nos tecidos devido à elevada exposição à radiação dos testes de imagem dificultem o crescimento do mercado europeu de diagnóstico do cancro do rim no período de previsão.

A Data Bridge Market Research analisa que o mercado de diagnóstico de cancro renal deverá atingir um valor de 3.572,63 milhões de dólares até 2030, com um CAGR de 6,1% durante o período de previsão. A imagem é responsável pelo maior segmento de tipos de testes do mercado devido à crescente procura de dispositivos inteligentes, e o aumento dos gastos com a saúde acelerou a procura de dispositivos médicos inteligentes.

Métrica de reporte	Detalhes
Período de previsão	2023 a 2030
Ano base	2022
Anos históricos	2021 (personalizável para 2020-2016)
Unidades Quantitativas	Receita em milhões de dólares, volumes em unidades, preços em dólares
Segmentos cobertos	Por tipo de teste (imagiologia, teste de biomarcador, análise ao sangue, biópsia, teste genético e outros), estádio de cancro (estádio I, estádio II, estádio III e estádio IV), tipo de tumor (carcinoma de células renais, carcinoma de células renais de células claras , carcinoma de células renais de células não claras), produto (produtos baseados em plataforma, produtos baseados em instrumentos, kits e reagentes e outros consumíveis), tecnologia (hibridização in situ fluorescente, sequenciação de nova geração, fluorimunoensaio , hibridização genómica comparativa, imunohistoquímica e outros) , Aplicação (rastreio, diagnóstico e preditivo, prognóstico e investigação), utilizador final (hospitais, centros de diagnóstico, centros de investigação oncológica, institutos académicos, centros de cirurgia ambulatória e outros), canal de distribuição (concurso direto, vendas a retalho e outros) .
Países abrangidos	Alemanha, França, Reino Unido, Itália, Rússia, Espanha, Países Baixos, Suíça, Noruega, Polónia, Suécia, Bélgica, Turquia, Dinamarca, Finlândia e restante Europa.
Participantes do mercado abrangidos	Siemens Healthcare GmbH, Koninklijke Philips NV, FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Myriad Genetics, Inc., CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Illumina Inc., Ambry Genetics, Invitae Corporation, General Electric Company, Centogene NV, GenPath, Creative Diagnostics, GeneDx LLC, Blueprint Genetics Oy, BioVendor R&D e CD Genomics e BD, entre outros

Definição de mercado

O cancro renal, vulgarmente conhecido como cancro do rim, é uma condição na qual as células renais se transformam em tumores malignos (cancerígenos) e se expandem incontrolavelmente. Um dos 10 tipos de cancro mais prevalentes é o cancro do rim. O cancro do rim é fatal e o processo de diagnóstico também apresenta problemas de segurança; não é rentável. Os doentes oncológicos podem ser hospitalizados e receber uma variedade de terapias, como cirurgia, radioterapia e terapia sistémica. Cerca de 40% dos crescimentos renais são pequenas massas localizadas. Localizado refere-se a um tumor que não se espalhou a partir da sua localização original. As massas renais não podem ser detectadas com procedimentos laboratoriais regulares. O diagnóstico de cancro renal inclui procedimentos de biópsia, análises ao sangue e exames de imagem. Terapias avançadas para o cancro renal, como a imunoterapia, radioterapia, etc., são recomendadas. Devido aos métodos de ponta, os procedimentos não cirúrgicos como a crioablação (que congela as células cancerígenas) e a ablação por radiofrequência são por vezes utilizados para tratar tumores renais mais pequenos (células cancerígenas pelo calor).

O cancro do rim pode ser difícil de diagnosticar porque, apesar da sua vasta gama de sinais e sintomas, são inespecíficos e podem estar associados a outras condições médicas mais generalizadas. Mais de 43.000 homens e 25.000 mulheres são diagnosticados com cancro do rim e da pélvis renal por ano, e 9.000 homens e 5.000 mulheres morrem em consequência desta doença. No entanto, espera-se que os regulamentos e normas rigorosos para a aprovação e comercialização de produtos para o diagnóstico do cancro do rim restrinjam o crescimento do mercado.

Dinâmica do mercado de diagnóstico do cancro do rim na Europa

Esta secção trata da compreensão dos impulsionadores do mercado, vantagens, oportunidades, restrições e desafios. Tudo isto é discutido em detalhe abaixo:

Motoristas

Crescente prevalência de cancro renal

Todas as idades podem ser afetadas por este tipo de cancro. O cancro do rim pode ser difícil de diagnosticar porque, apesar da sua vasta gama de sinais e sintomas, são inespecíficos e podem estar associados a outras condições médicas mais generalizadas. O cancro do rim geralmente não apresenta sinais ou sintomas nos seus estágios iniciais. Com o tempo, podem ocorrer sinais e sintomas, incluindo sangue na urina, que pode parecer cor-de-rosa, vermelho ou cor de cola, dor nas costas ou nos lados que não desaparece, perda de apetite, perda de peso inexplicável, fadiga e febre. Nos adultos, o cancro do rim é o tipo mais comum de cancro. As crianças pequenas têm maior probabilidade de desenvolver um tipo de cancro renal chamado tumor de Wilms. O cancro do rim (também conhecido como cancro do rim ou adenocarcinoma de células renais) é o 14º cancro mais comum em todo o mundo. É o 9º entre os homens e o 14º entre as mulheres. Em 2020, foram diagnosticados mais de 30 mil novos casos de cancro renal.

Devido a vários factores de risco, como o tabagismo, a obesidade, a pressão arterial elevada (hipertensão) ou antecedentes familiares de cancro do rim, o número de doentes com cancro do rim está a aumentar na Europa e a tornar-se um problema socioeconómico significativo. Assim, o número crescente de doentes com cancro do rim aumenta a procura de produtos de diagnóstico do cancro do rim que actuam como impulsionadores do mercado europeu de diagnóstico do cancro do rim.

Aumento dos procedimentos de diagnóstico para o cancro renal

As técnicas utilizadas para diagnosticar o cancro do rim incluem a ecografia, a tomografia computorizada (TC), a ressonância magnética (RM) e, por vezes, a tomografia por emissão de positrões (PET). O tratamento do cancro do rim com taxa de crescimento lenta pode envolver monitorização. A quimioterapia para tumores malignos é ocasionalmente combinada com radioterapia e transplante de células estaminais. O aumento das taxas de cancro tem sido um fator impulsionador para a crescente aprovação de produtos de diagnóstico.

Assim, o aumento das aprovações de produtos de diagnóstico levou a um aumento do número de produtos altamente eficientes no mercado para o tratamento do diagnóstico do cancro do rim. Espera-se que isto atue como um motor para o crescimento do mercado europeu de diagnóstico do cancro do rim.

Oportunidade

Crescente preferência por exames de saúde preventivos

O check-up preventivo de saúde são ações preventivas realizadas para a deteção inicial do cancro do rim. Além disso, uma preferência crescente por exames de saúde preventivos proporciona uma salvaguarda contra a provável exposição a qualquer doença no futuro.

A sensibilização para promover o rastreio é a componente mais importante da prevenção do cancro do rim. O check-up consiste na identificação do cancro e exames de fatores de risco para limitar a perda numa fase inicial.

O check-up preventivo do cancro do rim é realizado com o auxílio de diversos exames de diagnóstico, que incluem biópsia, imunohistoquímica, rastreio do cancro, ressonância magnética e entre outros.

As pessoas são relativamente mais propensas a doenças cancerígenas renais. Por conseguinte, exigem a realização de check-ups regulares para facilitar aos médicos o desenvolvimento de uma compreensão das doenças e para prestar um melhor tratamento a um doente que sofre de cancro, pela razão pela qual se espera que a crescente preferência por check-ups preventivos de saúde atue como um impulsionador para o crescimento do mercado europeu de diagnóstico do cancro do rim.

Restrição/Desafio

Regulamentação e normas rigorosas para aprovação e comercialização de produtos para diagnóstico de cancro renal

As rigorosas regulamentações para a comercialização de qualquer produto no mercado estão a revelar-se um grande desafio para os fabricantes de produtos de diagnóstico do cancro na Europa, que possuem regulamentações e um organismo diferente para os procedimentos regulamentares.

Os fabricantes têm primeiro de verificar a aprovação da marca CE para a comercialização dos seus produtos no mercado europeu. Espera-se que as rigorosas políticas regulamentares atrapalhem o desenvolvimento do mercado de diagnóstico do cancro. A exigência regulamentar para aprovações de comercialização ou certificação CE e aplicação de leis e regulamentos pode levar a grandes mudanças nos negócios ou ao pagamento de penalizações, incluindo a potencial perda de licenças comerciais. Os recursos e custos necessários para cumprir estas leis, regras e regulamentos são elevados.

Os requisitos regulamentares para as aprovações de comercialização, a declaração de conformidade e o tempo necessário para a revisão regulamentar podem variar de produto para produto. A empresa que não consegue a aprovação regulamentar prejudica o negócio porque sem obter a aprovação ou sem conseguir que a CE marque a aprovação nos produtos, os fabricantes não conseguem lançar os seus produtos no mercado europeu e, por esse motivo, regulamentos e normas rigorosas para a espera -se que a aprovação e comercialização de produtos de diagnóstico do cancro renal funcionem como uma restrição para o mercado europeu de diagnóstico do cancro renal.

Desenvolvimentos recentes

Em novembro de 2022, a Koninklijke Philips NV anunciou o lançamento na Europa de uma solução de ecografia portátil compacta de próxima geração na reunião anual da Sociedade Radiológica da América do Norte (RSNA) para levar a mais doentes a qualidade de diagnóstico associada aos sistemas de ultrassons premium baseados em carrinho. É portátil e versátil, com boa qualidade de imagem ou desempenho. É compatível com os sistemas de ultrassons Philips Affiniti e transdutor EPIQ. Isto ajudou a empresa a expandir o seu portfólio de produtos.
Em outubro de 2022, a General Electric Company colaborou com vários institutos de investigação como os hospitais da Universidade de Cambridge, Sophia Genetics e, anteriormente, com a Optellum para utilizar dados de imagem em colaboração com a inteligência artificial. Isto ajudará a reduzir o tempo de diagnóstico de vários tipos de cancro e a prestar cuidados personalizados aos pacientes. Isto ajudou a empresa a alargar os seus horizontes no diagnóstico de cancro.
Em julho de 2022, a Canon Medical Systems USA Inc. anunciou a conclusão da aquisição da NXC Imaging, um distribuidor e prestador de serviços de equipamentos de imagiologia médica localizado em Minnesota, EUA.

Âmbito do mercado de diagnóstico de cancro renal na Europa

O mercado europeu de diagnóstico do cancro do rim está segmentado em oito segmentos notáveis com base no tipo de teste, estádio do cancro, tipo de tumor, produto, aplicação, tecnologia, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.

Tipo de teste

TESTE DE IMAGEM
TESTE DE BIOMARCADOR
TESTE DE SANGUE
BIÓPSIA
TESTE GENÉTICO
OUTROS

Com base no tipo de teste, o mercado europeu de diagnóstico do cancro do rim está segmentado em imagem, teste de biomarcadores, exame de sangue, biópsia, testes genéticos, entre outros.

Estágio do cancro

ESTÁGIO I
ESTÁGIO II
ESTÁGIO III
ESTÁGIO IV

Com base no estádio do cancro, o mercado europeu de diagnóstico do cancro do rim está segmentado no estádio I, estádio II, estádio III e estádio IV.

Tipo de tumor

CARCINOMA DE CÉLULAS RENAIS
CARCINOMA DE CÉLULAS RENAIS DE CÉLULAS CLARAS
CARCINOMA DE CÉLULAS RENAIS DE CÉLULAS NÃO CLARAS

Com base no tipo de tumor, o mercado europeu de diagnóstico do cancro do rim está segmentado em carcinoma de células renais, carcinoma de células renais de células claras e carcinoma de células renais de células não claras.

Produto

PRODUTOS BASEADOS EM PLATAFORMA
PRODUTOS BASEADOS EM INSTRUMENTOS
KITS E REAGENTES
OUTROS CONSUMÍVEIS

Com base no produto, o mercado europeu de diagnóstico do cancro do rim está segmentado em produtos baseados em instrumentos, produtos baseados em plataformas, kits e reagentes e outros consumíveis.

Tecnologia

HIBRIDIZAÇÃO FLUORESCENTE IN SITU
SEQUENCIAÇÃO DE PRÓXIMA GERAÇÃO
FLUORIMUNOASSAO
HIBRIDIZAÇÃO GENÓMICA COMPARATIVA
IMUNO-HISTOQUÍMICA
OUTROS

Com base na tecnologia, o mercado europeu de diagnóstico do cancro renal está segmentado em hibridização fluorescente in situ, sequenciação de nova geração, fluorimunoensaio, hibridização genómica comparativa, imunohistoquímica, entre outros.

Aplicação

TRIAGEM
DIAGNÓSTICO E PREDITIVO
PROGNÓSTICO
INVESTIGAÇÃO

Com base na aplicação, o mercado europeu de diagnóstico do cancro do rim está segmentado em rastreio, diagnóstico e preditivo, prognóstico e investigação.

Utilizador final

HOSPITAIS
CENTROS DE INVESTIGAÇÃO DE CÂNCER
INSTITUTOS ACADÉMICOS
CENTROS DE DIAGNÓSTICO
CENTROS CIRÚRGICOS AMBULATÓRIOS
OUTROS

Com base nos utilizadores finais, o mercado europeu de diagnóstico do cancro do rim está segmentado em hospitais, centros de diagnóstico, centros de investigação do cancro, institutos académicos, centros de cirurgia ambulatória, entre outros.

Canal de Distribuição

PROPOSTAS DIRETAS
VENDAS NO VAREJO
OUTROS

Com base no canal de distribuição, o mercado europeu de diagnóstico do cancro do rim está segmentado em licitação direta, vendas a retalho e outros.

Análise/perspetivas regionais do mercado de diagnóstico do cancro do rim na Europa

O mercado europeu de diagnóstico do cancro do rim é analisado e são fornecidas informações sobre o tamanho do mercado com base no país, tipo de teste, estádio do cancro, tipo de tumor, produto, aplicação, tecnologia, utilizador final e canal de distribuição.

Os países abrangidos neste relatório de mercado são a Alemanha, França, Reino Unido, Itália, Rússia, Espanha, Países Baixos, Suíça, Noruega, Polónia, Suécia, Bélgica, Turquia, Dinamarca, Finlândia e o resto da Europa.

O Reino Unido domina a região da Europa devido à produção em massa de hardware e à crescente procura dos mercados emergentes e à expansão das indústrias de saúde.

A secção de países do relatório também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas europeias e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, e o impacto dos canais de vendas, ao mesmo tempo que se fornece uma análise de previsão dos dados do país .

Cenário competitivo e análise da quota de mercado do diagnóstico de cancro renal na Europa

O panorama competitivo do mercado de diagnóstico do cancro do rim fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em I&D, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, aprovações de produtos, largura e amplitude do produto, domínio de aplicação e tipo de produto curva da linha de vida. Os dados fornecidos acima estão apenas relacionados com o foco da empresa no mercado de diagnóstico do cancro do rim.

Alguns dos principais players que operam no mercado são a Siemens Healthcare GmbH, Koninklijke Philips NV, FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Myriad Genetics, Inc., CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Illumina Inc., Ambry Genetics, Invitae Corporation, General Electric Company, Centogene NV, GenPath, Creative Diagnostics, GeneDx LLC, Blueprint Genetics Oy, BioVendor R&D e CD Genomics e BD, entre outros.

SKU-69722

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Click on image to enlarge

Painel interativo de análise de dados
Painel de análise da empresa para oportunidades de elevado potencial de crescimento
Acesso de analista de pesquisa para personalização e customização. consultas
Análise da concorrência com painel interativo
Últimas notícias, atualizações e atualizações Análise de tendências
Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência

Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE EUROPE KIDNEY CANCER DIAGNOSTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 TEST TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S 5 FORCES

4.3 EPIDEMIOLOGY

4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES

4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES

5 INDUSTRY INSIGHTS

6 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 GROWING PREVALENCE OF KIDNEY CANCER

7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER

7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT

7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER

7.2 RESTRAINTS

7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS

7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS

7.3 OPPORTUNITIES

7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS

7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS

7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE

7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS

7.4 CHALLENGES

7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS

7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS

8 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE

8.1 OVERVIEW

8.2 IMAGING

8.2.1 COMPUTED TOMOGRAPHY

8.2.2 ULTRASOUND

8.2.3 MAGNETIC RESONANCE IMAGING (MRI)

8.2.4 ANGIOGRAPHY

8.2.5 X-RAY

8.2.6 OTHERS

8.3 BLOOD TEST

8.4 BIOPSY

8.4.1 FINE NEEDLE ASPIRATION

8.4.2 NEEDLE CORE BIOPSY

8.5 BIOMARKER TEST

8.5.1 AQUAPORIN 1 (AQP1)

8.5.2 PERILIPIN (PLIN2)

8.5.3 N-METHYLTRANSFERASE (NMNT)

8.5.4 L-PLASTIN (LCP-1)

8.5.5 NM23A

8.6 GENETIC TEST

8.7 OTHERS

9 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE

9.1 OVERVIEW

9.2 STAGE I

9.3 STAGE II

9.4 STAGE III

9.5 STAGE IV

10 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE

10.1 OVERVIEW

10.2 RENAL CELL CARCINOMA

10.2.1 IMAGING

10.2.2 BLOOD TEST

10.2.3 BIOPSY

10.2.4 BIOMARKER TEST

10.2.5 GENETIC TEST

10.2.6 OTHERS

10.3 CLEAR CELL RENAL CELL CARCINOMA

10.3.1 IMAGING

10.3.2 BLOOD TEST

10.3.3 BIOPSY

10.3.4 BIOMARKER TEST

10.3.5 GENETIC TEST

10.3.6 OTHERS

10.4 NON CLEAR CELL RENAL CELL CARCINOMA

10.4.1 PAPILLARY RENAL CELL CARCINOMA

10.4.1.1 IMAGING

10.4.1.2 BLOOD TEST

10.4.1.3 BIOPSY

10.4.1.4 BIOMARKER TEST

10.4.1.5 GENETIC TEST

10.4.1.6 OTHERS

10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA

10.4.2.1 IMAGING

10.4.2.2 BLOOD TEST

10.4.2.3 BIOPSY

10.4.2.4 BIOMARKER TEST

10.4.2.5 GENETIC TEST

10.4.2.6 OTHERS

11 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT

11.1 OVERVIEW

11.2 INSTRUMENT BASED PRODUCTS

11.2.1 IMAGING

11.2.2 BIOPSY

11.3 PLATFORM BASED PRODUCTS

11.3.1 NEXT GENERATION SEQUENCING

11.3.2 MICROARRAYS

11.3.3 PCR

11.3.4 OTHERS

11.4 KITS AND REAGENTS

11.4.1 RENAL CANCER PANELS

11.4.2 RENAL CANCER ANTIBODIES

11.5 OTHER CONSUMABLES

12 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY

12.1 OVERVIEW

12.2 FLUORESCENT IN SITU HYBRIDIZATION

12.3 NEXT GENERATION SEQUENCING

12.4 FLUORIMMUNOASSAY

12.5 COMPARATIVE GENOMIC HYBRIDIZATION

12.6 IMMUNOHISTOCHEMICAL

12.7 OTHERS

13 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION

13.1 OVERVIEW

13.2 SCREENING

13.2.1 INSTRUMENT BASED PRODUCTS

13.2.2 PLATFORM BASED PRODUCTS

13.2.3 KITS AND REAGENTS

13.2.4 OTHER CONSUMABLES

13.3 DIAGNOSTIC AND PREDICTIVE

13.3.1 INSTRUMENT BASED PRODUCTS

13.3.2 PLATFORM BASED PRODUCTS

13.3.3 KITS AND REAGENTS

13.3.4 OTHER CONSUMABLES

13.4 PROGNOSTIC

13.4.1 INSTRUMENT BASED PRODUCTS

13.4.2 PLATFORM BASED PRODUCTS

13.4.3 KITS AND REAGENTS

13.4.4 OTHER CONSUMABLES

13.5 RESEARCH

13.5.1 INSTRUMENT BASED PRODUCTS

13.5.2 PLATFORM BASED PRODUCTS

13.5.3 KITS AND REAGENTS

13.5.4 OTHER CONSUMABLES

14 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 DIAGNOSTIC CENTERS

14.4 CANCER RESEARCH CENTERS

14.5 ACADEMIC INSTITUTES

14.6 AMBULATORY SURGICAL CENTERS

14.7 OTHERS

15 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 RETAIL SALES

15.4 OTHERS

16 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION

16.1 EUROPE

16.1.1 GERMANY

16.1.2 FRANCE

16.1.3 UNITED KINGDOM

16.1.4 ITALY

16.1.5 SPAIN

16.1.6 RUSSIA

16.1.7 NETHERLANDS

16.1.8 POLAND

16.1.9 SWITZERLAND

16.1.10 BELGIUM

16.1.11 SWEDEN

16.1.12 NORWAY

16.1.13 DENMARK

16.1.14 FINLAND

16.1.15 TURKEY

16.1.16 REST OF EUROPE

17 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: EUROPE

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 CANON MEDICAL SYSTEMS CORPORATION

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY PROFILE

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 KONINKLIJKE PHILIPS N.V.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY PROFILE

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 GENERAL ELECTRIC COMPANY

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY PROFILE

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENTS

19.4 SIEMENS HEALTHCARE GMBH

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY PROFILE

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 GRAIL

19.5.1 COMPANY SNAPSHOT

19.5.2 PRODUCT PORTFOLIO

19.5.3 RECENT DEVELOPMENTS

19.6 AMBRY GENETICS

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 BIOVENDOR R&D

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 BLUEPRINT GENETICS OY.

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 CD GENOMICS

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENT

19.1 CENTOGENE N.V.

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 CREATIVE DIAGNOSTICS

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENT

19.12 FUJIFILM CORPORATION

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 GENEDX, LLC

19.13.1 COMPANY SNAPSHOT

19.13.2 REVENUE ANALYSIS

19.13.3 PRODUCT PORTFOLIO

19.13.4 RECENT DEVELOPMENT

19.14 GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 ILLUMINA, INC.

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 INVITAE CORPORATION

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENT

19.17 LABORATORY CORPORATION OF AMERICA HOLDINGS

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENTS

19.18 MYRIAD GENETICS, INC.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

19.19 THERMO FISHER SCIENTIFIC INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENT

19.2 QIAGEN

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

Lista de Tabela

TABLE 1 ESTIMATED NEW CANCER CASES AND DEATHS

TABLE 2 APPROVED DIAGNOSTICS OF KIDNEY CANCER

TABLE 3 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 4 EUROPE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 EUROPE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 6 EUROPE BLOOD TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 EUROPE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 EUROPE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 9 EUROPE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 EUROPE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 11 EUROPE GENETIC TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 EUROPE OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 14 EUROPE STAGE I IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 EUROPE STAGE II IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 EUROPE STAGE III IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 EUROPE STAGE IV IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 19 EUROPE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 EUROPE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 21 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 23 EUROPE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 EUROPE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 25 EUROPE PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 26 EUROPE CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 27 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 28 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 30 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 31 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 32 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 34 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 35 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 36 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 38 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 39 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 40 EUROPE OTHER CONSUMABLES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 42 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 EUROPE NEXT GENERATION SEQUENCING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 EUROPE FLUORIMMUNOASSAY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 EUROPE IMMUNOHISTOCHEMICAL IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 EUROPE OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 49 EUROPE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 EUROPE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 51 EUROPE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 52 EUROPE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 53 EUROPE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 54 EUROPE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 55 EUROPE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 56 EUROPE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 57 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 58 EUROPE HOSPITALS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 EUROPE DIAGNOSTIC CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 60 EUROPE CANCER RESEARCH CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 61 EUROPE ACADEMIC INSTITUTES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 62 EUROPE AMBULATORY SURGICAL CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 63 EUROPE OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 64 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 65 EUROPE DIRECT TENDER IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 66 EUROPE RETAIL SALES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 67 EUROPE OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 68 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 69 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 70 EUROPE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 71 EUROPE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 72 EUROPE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 73 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 74 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 75 EUROPE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 76 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 77 EUROPE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 78 EUROPE PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 79 EUROPE CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 80 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 81 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 82 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 83 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 84 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 85 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 86 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 87 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 88 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 89 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 90 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 91 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 92 EUROPE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 93 EUROPE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 94 EUROPE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 95 EUROPE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 96 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 97 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 98 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 99 GERMANY IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 100 GERMANY BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 101 GERMANY BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 102 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 103 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 104 GERMANY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 105 GERMANY CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 106 GERMANY NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 107 GERMANY PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 108 GERMANY CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 109 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 110 GERMANY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 111 GERMANY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 112 GERMANY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 113 GERMANY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 114 GERMANY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 115 GERMANY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 116 GERMANY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 117 GERMANY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 118 GERMANY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 119 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 120 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 121 GERMANY SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 122 GERMANY SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 123 GERMANY PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 124 GERMANY RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 125 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 126 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 127 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 128 FRANCE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 129 FRANCE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 130 FRANCE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 131 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 132 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 133 FRANCE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 134 FRANCE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 135 FRANCE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 136 FRANCE PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 137 FRANCE CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 138 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 139 FRANCE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 140 FRANCE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 141 FRANCE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 142 FRANCE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 143 FRANCE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 144 FRANCE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 145 FRANCE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 146 FRANCE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 147 FRANCE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 148 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 149 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 150 FRANCE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 151 FRANCE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 152 FRANCE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 153 FRANCE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 154 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 155 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 156 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 157 UNITED KINGDOM IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 158 UNITED KINGDOM BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 159 UNITED KINGDOM BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 160 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 161 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 162 UNITED KINGDOM RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 163 UNITED KINGDOM CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 164 UNITED KINGDOM NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 165 UNITED KINGDOM PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 166 UNITED KINGDOM CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 167 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 168 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 169 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 170 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 171 UNITED KINGDOM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 172 UNITED KINGDOM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 173 UNITED KINGDOM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 174 UNITED KINGDOM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 175 UNITED KINGDOM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 176 UNITED KINGDOM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 177 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 178 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 179 UNITED KINGDOM SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 180 UNITED KINGDOM DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 181 UNITED KINGDOM PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 182 UNITED KINGDOM RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 183 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 184 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 185 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 186 ITALY IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 187 ITALY BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 188 ITALY BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 189 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 190 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 191 ITALY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 192 ITALY CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 193 ITALY NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 194 ITALY PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 195 ITALY CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 196 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 197 ITALY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 198 ITALY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 199 ITALY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 200 ITALY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 201 ITALY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 202 ITALY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 203 ITALY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 204 ITALY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 205 ITALY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 206 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 207 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 208 ITALY SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 209 ITALY DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 210 ITALY PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 211 ITALY RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 212 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 213 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 214 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 215 SPAIN IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 216 SPAIN BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 217 SPAIN BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 218 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 219 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 220 SPAIN RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 221 SPAIN CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 222 SPAIN NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 223 SPAIN PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 224 SPAIN CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 225 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 226 SPAIN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 227 SPAIN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 228 SPAIN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 229 SPAIN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 230 SPAIN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 231 SPAIN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 232 SPAIN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 233 SPAIN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 234 SPAIN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 235 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 236 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 237 SPAIN SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 238 SPAIN DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 239 SPAIN PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 240 SPAIN RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 241 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 242 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 243 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 244 RUSSIA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 245 RUSSIA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 246 RUSSIA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 247 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 248 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 249 RUSSIA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 250 RUSSIA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 251 RUSSIA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 252 RUSSIA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 253 RUSSIA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 254 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 255 RUSSIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 256 RUSSIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 257 RUSSIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 258 RUSSIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 259 RUSSIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 260 RUSSIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 261 RUSSIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 262 RUSSIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 263 RUSSIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 264 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 265 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 266 RUSSIA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 267 RUSSIA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 268 RUSSIA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 269 RUSSIA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 270 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 271 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 272 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 273 NETHERLANDS IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 274 NETHERLANDS BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 275 NETHERLANDS BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 276 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 277 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 278 NETHERLANDS RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 279 NETHERLANDS CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 280 NETHERLANDS NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 281 NETHERLANDS PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 282 NETHERLANDS CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 283 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 284 NETHERLANDS INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 285 NETHERLANDS INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 286 NETHERLANDS INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 287 NETHERLANDS PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 288 NETHERLANDS PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 289 NETHERLANDS PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 290 NETHERLANDS KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 291 NETHERLANDS KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 292 NETHERLANDS KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 293 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 294 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 295 NETHERLANDS SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 296 NETHERLANDS DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 297 NETHERLANDS PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 298 NETHERLANDS RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 299 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 300 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 301 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 302 POLAND IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 303 POLAND BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 304 POLAND BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 305 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 306 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 307 POLAND RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 308 POLAND CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 309 POLAND NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 310 POLAND PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 311 POLAND CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 312 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 313 POLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 314 POLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 315 POLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 316 POLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 317 POLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 318 POLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 319 POLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 320 POLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 321 POLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 322 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 323 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 324 POLAND SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 325 POLAND DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 326 POLAND PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 327 POLAND RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 328 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 329 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 330 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 331 SWITZERLAND IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 332 SWITZERLAND BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 333 SWITZERLAND BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 334 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 335 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 336 SWITZERLAND RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 337 SWITZERLAND CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 338 SWITZERLAND NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 339 SWITZERLAND PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 340 SWITZERLAND CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 341 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 342 SWITZERLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 343 SWITZERLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 344 SWITZERLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 345 SWITZERLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 346 SWITZERLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 347 SWITZERLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 348 SWITZERLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 349 SWITZERLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 350 SWITZERLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 351 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 352 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 353 SWITZERLAND SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 354 SWITZERLAND DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 355 SWITZERLAND PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 356 SWITZERLAND RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 357 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 358 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 359 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 360 BELGIUM IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 361 BELGIUM BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 362 BELGIUM BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 363 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 364 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 365 BELGIUM RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 366 BELGIUM CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 367 BELGIUM NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 368 BELGIUM PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 369 BELGIUM CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 370 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 371 BELGIUM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 372 BELGIUM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 373 BELGIUM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 374 BELGIUM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 375 BELGIUM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 376 BELGIUM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 377 BELGIUM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 378 BELGIUM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 379 BELGIUM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 380 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 381 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 382 BELGIUM SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 383 BELGIUM DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 384 BELGIUM PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 385 BELGIUM RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 386 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 387 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 388 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 389 SWEDEN IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 390 SWEDEN BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 391 SWEDEN BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 392 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 393 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 394 SWEDEN RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION))

TABLE 395 SWEDEN CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 396 SWEDEN NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 397 SWEDEN PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 398 SWEDEN CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 399 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 400 SWEDEN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 401 SWEDEN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 402 SWEDEN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 403 SWEDEN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 404 SWEDEN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 405 SWEDEN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 406 SWEDEN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 407 SWEDEN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 408 SWEDEN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 409 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 410 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 411 SWEDEN SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 412 SWEDEN DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 413 SWEDEN PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 414 SWEDEN RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 415 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 416 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 417 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 418 NORWAY IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 419 NORWAY BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 420 NORWAY BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 421 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 422 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 423 NORWAY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 424 NORWAY CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 425 NORWAY NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 426 NORWAY PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 427 NORWAY CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 428 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 429 NORWAY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 430 NORWAY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 431 NORWAY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 432 NORWAY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 433 NORWAY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 434 NORWAY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 435 NORWAY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 436 NORWAY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 437 NORWAY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 438 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 439 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 440 NORWAY SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 441 NORWAY DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 442 NORWAY PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 443 NORWAY RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 444 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 445 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 446 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 447 DENMARK IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 448 DENMARK BIOPSY TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 449 DENMARK BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 450 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 451 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 452 DENMARK RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 453 DENMARK CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 454 DENMARK NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 455 DENMARK PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 456 DENMARK CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 457 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 458 DENMARK INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 459 DENMARK INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 460 DENMARK INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 461 DENMARK PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 462 DENMARK PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 463 DENMARK PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 464 DENMARK KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 465 DENMARK KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 466 DENMARK KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 467 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 468 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 469 DENMARK SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 470 DENMARK DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 471 DENMARK PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 472 DENMARK RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 473 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 474 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 475 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 476 FINLAND IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 477 FINLAND BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 478 FINLAND BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 479 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 480 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 481 FINLAND RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 482 FINLAND CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 483 FINLAND NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 484 FINLAND PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 485 FINLAND CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 486 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 487 FINLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 488 FINLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 489 FINLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 490 FINLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 491 FINLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 492 FINLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 493 FINLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 494 FINLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 495 FINLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 496 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 497 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 498 FINLAND SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 499 FINLAND DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 500 FINLAND PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 501 FINLAND RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 502 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 503 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 504 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 505 TURKEY IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 506 TURKEY BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 507 TURKEY BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 508 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 509 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 510 TURKEY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 511 TURKEY CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 512 TURKEY NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 513 TURKEY PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 514 TURKEY CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 515 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 516 TURKEY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 517 TURKEY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 518 TURKEY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 519 TURKEY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 520 TURKEY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 521 TURKEY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 522 TURKEY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 523 TURKEY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 524 TURKEY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 525 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 526 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 527 TURKEY SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 528 TURKEY DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 529 TURKEY PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 530 TURKEY RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 531 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 532 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 533 REST OF EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

Lista de Figura

FIGURE 1 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 11 GROWING AWARENESS OF KIDNEY CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE KIDNEY CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030

FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE KIDNEY CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE KIDNEY CANCER DIAGNOSTICS MARKET

FIGURE 14 KIDNEY CANCER INCIDENCE, BOTH SEXES, BY REGION (2020)

FIGURE 15 KIDNEY CANCER MORTALITY, BOTH SEXES, BY REGION (2020)

FIGURE 16 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022

FIGURE 17 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 18 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030)

FIGURE 19 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE

FIGURE 20 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE , 2022

FIGURE 21 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, 2023-2030 (USD MILLION)

FIGURE 22 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, CAGR (2023-2030)

FIGURE 23 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, LIFELINE CURVE

FIGURE 24 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2022

FIGURE 25 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2023-2030 (USD MILLION)

FIGURE 26 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, CAGR (2023-2030)

FIGURE 27 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, LIFELINE CURVE

FIGURE 28 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2022

FIGURE 29 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2023-2030 (USD MILLION)

FIGURE 30 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, CAGR (2023-2030)

FIGURE 31 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, LIFELINE CURVE

FIGURE 32 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022

FIGURE 33 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 34 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 35 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE

FIGURE 36 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2022

FIGURE 37 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 38 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, CAGR (2023-2030)

FIGURE 39 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, LIFELINE CURVE

FIGURE 40 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2022

FIGURE 41 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION)

FIGURE 42 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030)

FIGURE 43 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE

FIGURE 44 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022

FIGURE 45 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 46 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 47 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 48 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 49 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 50 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 51 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 52 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 53 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

View Detailed Information

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

What is the forecasted growth of this market?

The Europe Kidney Cancer Diagnostics Market will sky-rocket a 6.1% CAGR from 2023 to 2030.

What will be the market value in the future?

The Europe Kidney Cancer Diagnostics Market will bag USD 3,572.63 million by 2030.

Which market segments are covered in this report?

The Europe Kidney Cancer Diagnostics Market report is categorized by test type, cancer stage, tumor type, product, application, technology, end user and distribution mode.

Which region dominates the market ?

The Europe Kidney Cancer Diagnostics Market covers the geographical locations of Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, and the rest of Europe.

Mercado Europeu de Diagnóstico do Cancro do Renal – Tendências da Indústria e Previsão para 2030

Mercado Europeu de Diagnóstico do Cancro do Renal – Tendências da Indústria e Previsão para 2030

Europe Kidney Cancer Diagnostics Market

CAGR : 6.10 %

Análise e dimensão do mercado de diagnóstico de cancro renal na Europa

Dinâmica do mercado de diagnóstico do cancro do rim na Europa

Âmbito do mercado de diagnóstico de cancro renal na Europa

Análise/perspetivas regionais do mercado de diagnóstico do cancro do rim na Europa

Cenário competitivo e análise da quota de mercado do diagnóstico de cancro renal na Europa

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Relatórios

Informações de mercado

Apoiar

Soluções

Mercado Europeu de Diagnóstico do Cancro do Renal – Tendências da Indústria e Previsão para 2030

Mercado Europeu de Diagnóstico do Cancro do Renal – Tendências da Indústria e Previsão para 2030

Europe Kidney Cancer Diagnostics Market

CAGR : 6.10 %

Análise e dimensão do mercado de diagnóstico de cancro renal na Europa

Dinâmica do mercado de diagnóstico do cancro do rim na Europa

Âmbito do mercado de diagnóstico de cancro renal na Europa

Análise/perspetivas regionais do mercado de diagnóstico do cancro do rim na Europa

Cenário competitivo e análise da quota de mercado do diagnóstico de cancro renal na Europa

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Navegue pelas páginas relacionadas